Skip to main content
Fig. 2 | Allergy, Asthma & Clinical Immunology

Fig. 2

From: Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks

Fig. 2

Time to beginning of symptom relief per A fixed-effects (base case) and B random-effects (sensitivity analysis) models. Hazard ratio (HR) values > 1 favor sebetralstat 300 mg over recombinant human C1 esterase inhibitor (rhC1INH) 50 IU/kg. CrI credible interval, MA meta-analysis, PGI-C Patient Global Impression of Change, TEQ Treatment Effect Questionnaire

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us